TAH3311

TAH3311 is an innovative oral dissolving film (ODF) formulation of apixaban developed by Taho Pharmaceuticals. It is designed to address the needs of patients who have difficulty swallowing tablets, such as stroke survivors, the elderly, and children. Apixaban is a direct Factor Xa inhibitor widely used for stroke prevention in non-valvular atrial fibrillation and for the treatment and prevention of thromboembolic disorders. TAH3311 offers a water-free alternative that rapidly dissolves on the tongue, improving dosing accuracy and reducing risks associated with tablet crushing or aspiration pneumonia. Clinical studies have demonstrated that TAH3311 is bioequivalent to standard apixaban tablets (Eliquis), supporting its use as a patient-centric anticoagulant therapy[1][2][4][5][6].

Other names

apixaban oral dissolving filmapixaban ODF